论文部分内容阅读
以表浅性乳头状膀胱肿瘤31例为对象,用BCG膀胱内注入疗法(膀注疗法)使肿瘤缩小及预防复发进行了研究。每周1次或3次把东京珠BCG80mg,用导入疗法向膀胱内注入共12次,17例(55％)获得显效、7例(23％)有效。显效病例按原样不动,有效及没变化病例,经尿道把残存肿瘤切除后用维持疗法。维持疗法仍按前述方法每2周注入6次,1～21个月为一疗程。4例分别在3、4、6和18个月复发,其余27例经3～32个月(平均22个月)观察没有复发,1年复发率9.6％,2年复发率14.5％。治疗前PPD皮下反应阳性的17例中有2例复发,治疗中PPD皮下反应阴
Twenty-one cases of superficial papillary bladder tumor were treated with BCG intravesical instillation (intrathecal injection) to reduce the size of the tumor and prevent relapse. One week or three times a week, Tokyo Bead BCG 80 mg was infused into the bladder a total of 12 times with the induction therapy. Seventeen (55%) patients were markedly effective and seven (23%) were effective. Effective cases unchanged as it is, effective and no change in the case, the residual tumor after transurethral resection with maintenance therapy. Maintenance therapy is still infused 6 times every two weeks according to the above method, and the course of treatment is from 1 to 21 months. 4 cases relapsed at 3, 4, 6 and 18 months respectively. The remaining 27 cases showed no relapse after 3 ~ 32 months (average 22 months). The recurrence rate was 9.6% at 1 year and 14.5% at 2 years. There were 2 relapse cases in 17 cases of PPD subcutaneous reaction before treatment, in which PPD subcutaneous reaction